UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On November 16, 2022, EyePoint Pharmaceuticals, Inc. posted an updated investor presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
Investor Presentation of EyePoint Pharmaceuticals, Inc. dated November 16, 2022 |
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
EYEPOINT PHARMACEUTICALS, INC. |
|
|
|
|
Date: |
November 16, 2022 |
By: |
/s/ George O. Elston |
|
|
|
George O. Elston |
Investor Presentation November 2022 Exhibit 99.1
Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a sustained delivery treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU®; the loss of pass-through reimbursement status for DEXYCU at the end of 2022; the success of current and future license agreements, including our agreements with Ocumension Therapeutics, Equinox Science and Betta Pharmaceuticals; termination or breach of current license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized. 2 | INVESTOR PRESENTATION
EYP-1901 in Phase 2 clinical trials Bioerodible Durasert® delivering vorolanib as single injection sustained delivery intravitreal (IVT) insert DAVIO 2 - potential 6-month treatment for wet AMD PAVIA - potential 9-month treatment for non-proliferative diabetic retinopathy (NPDR) Durasert® - proven IVT drug delivery Sustained ocular drug delivery Constant (zero-order kinetics) stable release of drug Safely administered to over 80,000 patient eyes across four FDA approved products Strong Balance Sheet $157 million of cash and investments on September 30, 2022 Cash runway into 2H 2024 Commercial franchise on target for 2022 break-even Compelling Pipeline Leverages Proven Durasert® IVT Drug Delivery Technology COMPANY OVERVIEW 3 | INVESTOR PRESENTATION
DURASERT® TECHNOLOGY 4 | INVESTOR PRESENTATION Safe Sustained Intravitreal Drug Delivery Used in four of six FDA approved intravitreal sustained delivery products Delivered by a single in-office IVT injection Continuous, stable release of drug Non-Erodible Products YUTIQ® (EyePoint) ILUVIEN® (Alimera) RETISERT® (B&L) VITRASERT® (B&L) Bioerodible: EYP-1901 No polyimide coating Initial drug burst from insert surface Constant, zero-order kinetic release over months
EYP-1901 utilizes a bioerodible formulation of Durasert for repeated IVT injections Sustained, zero-order kinetics drug release over 6-9 months in bioerodible formulation High drug load per insert Single insert is ~1/5,000 the volume of the vitreous YUTIQ® Non-Erodible Silicone Seal v 3.5 mm EYP-1901 Bioerodible v Up to 8.0 mm Polyimide Shell Bioerodible Matrix Polymer Cap 5 | INVESTOR PRESENTATION
Vorolanib selected after evaluation of over 100 tyrosine kinase inhibitors (TKIs) Intracellular binding of all vascular endothelial growth factor (VEGF) receptors Differentiated mechanism of action versus anti-VEGF biologics In-vivo studies demonstrate encouraging neuroprotection data Phase 1 and Phase 2 clinical trials as an oral therapy showed compelling efficacy data with no ocular toxicity observed1,2 Reduced off-target binding of receptors associated with TKI systemic side effects Vorolanib binds receptors of all VEGF growth factors WHY VOROLANIB? 6 | INVESTOR PRESENTATION Jackson et al. JAMA Ophthalmol 2017 2. Cohen MN et al. Br J Ophthalmol. 2021
Vorolanib binds receptors of all VEGF growth factors with strong affinity to VEGF receptor 2 - a receptor associated with blood vessel leakage VOROLANIB VOROLANIB VOROLANIB VEGF-A VEGF-B VEGF-C VEGF-D R1 | Inflammation R2 | Blood Vessel Leakage R3 | Blood Vessel Growth & Leakage 7 | INVESTOR PRESENTATION VEGF SIGNALING PATHWAYS VOROLANIB INHIBITS VEGFR Binds to the intracellular domain of tyrosine kinases Targets the angiogenic VEGF receptors R1, R2 and R3 with high potency
EYP-1901delivers VEGF receptor binding vorolanib in Bioerodible Durasert® EYP-1901 IS ~1/5000 OF VITREOUS EYP-1901 A single IVT injection of up to 3 inserts Bioerodible formulation of Durasert Initial drug burst from surface of insert to rapidly reach therapeutic levels in ocular tissues Zero order kinetics release expected to provide consistent drug levels through treatment course Vorolanib Binds receptors of all VEGF growth factors Different mechanism of action from ligand blocking anti-VEGF biologics
EYP-1901 PHASE 1 DAVIO CLINICAL TRIAL 12 MONTH RESULTS 9 | INVESTOR PRESENTATION
EYP-1901 Phase 1 DAVIO clinical trial enrolled 17 patients over four different dosages Primary Endpoint: Safety Ocular and non-ocular TEAEs through month-12 Secondary Endpoints Supplemental anti-VEGF therapy through 6-months Change in BCVA from baseline CST as measured by OCT RESULTS: MONTH 12 FULL READ EYP 1901: 7 – 10 DAYS LATER SCREENING VISIT SOC INJECTION MONTHS DAY0 1 2 3 4 5 6 7 8 9 10 11 12 LOW DOSE (440 μg) N=3 LOW-MID DOSE (1030 μg) N=1 MID DOSE (2060 μg) N=8 HIGH DOSE (3090 μg) N=5 10 | INVESTOR PRESENTATION
EYP-1901 Phase 1 DAVIO clinical trial demonstrated favorable overall safety data at 12-months meeting primary endpoint Ocular AEs of particular interest: No vitreous floaters No endophthalmitis No retinal detachment No implant migration in the anterior chamber No retinal vasculitis No posterior segment inflammation Ocular AEs observed: One eye: mild asymptomatic anterior chamber cell/flare; treated with Maxitrol® eyedrops – resolved in 8 days – no sequelae or recurrence One eye: asymptomatic vitreous hemorrhage from injection; observed No ocular serious adverse events (SAEs) No drug-related systemic SAEs No evidence of vorolanib-related ocular or systemic toxicity No Durasert-related toxicity or tolerance issues No dose limiting toxicity 11 | INVESTOR PRESENTATION
EYP-1901 Phase 1 DAVIO clinical trial demonstrated clinically significant reduction in treatment burden of 75% at 6-months 12 | INVESTOR PRESENTATION DAVIO 12-month final data SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –70% Low-mid dose (n=1) –100% Mid dose (n=8) –89% High dose (n=5) –44% Reduction in Average Monthly Treatment Burden at 6 Months SOC (Anti-VEGF) + EYP-1901 –1 year Month 0 1 year 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 Time Prior to Treatment with EYP-1901 Time Since EYP-1901
EYP-1901 Phase 1 DAVIO clinical trial continues clinically significant reduction in treatment burden of 73% at 12-months 13 | INVESTOR PRESENTATION SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –66% Low-mid dose (n=1) –100% Mid dose (n=8) –87% High dose (n=5) –41% Reduction in Average Monthly Treatment Burden at 12 Months SOC (Anti-VEGF) + EYP-1901 –1 year Month 0 1 year 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 Time Prior to Treatment with EYP-1901 Time Since EYP-1901
EYP-1901 Phase 1 DAVIO clinical trial demonstrated that 53% of patients did not require supplemental anti-VEGF treatment at 6-months 35% 47% 41% 41% 71% 76% 35% 35% 53% 82% 82% 100% Median time to supplemental anti-VEGF: 6 months
EYP-1901 Phase 1 DAVIO clinical trial met all objectives FAVORABLE SAFETY PROFILE Stabilization of mean BCVA and OCT throughout 6 months was achieved 53% supplemental anti-VEGF supplement injection free up to 6-months 79% reduction in treatment burden at 6-months No ocular SAEs reported No drug-related systemic SAEs reported Ocular AEs – majority are mild and expected DURASERT® VOROLANIB® SIX MONTHS MEDIAN TIME TO SUPPLEMENTAL ANTI-VEGF INJECTION POSITIVE EFFICACY & DURABILITY 15 | INVESTOR PRESENTATION
DAVIO PHASE 1 CLINICAL TRIAL SUBSET ANALYSIS - SUBJECTS WITH NO EXCESS FLUID AT SCREENING (N=9) 16 | INVESTOR PRESENTATION EYP-1901
BCVA: best corrected visual acuity Mean change in BCVA from screening visit (n = 9) Mean change in CST from screening visit (n = 9) For 9 eyes at 6 months with no excess fluid at screening BCVA = +1.2 letters at 5 months -0.4 letters at 6 months CST on OCT = +20.8 microns at 5 months -1.0 microns at 6 months OCT: optical coherence tomography; CST: central subfield thickness DAVIO Phase 1 clinical trial included 9 of 17 (53%) subjects with no “excess fluid” at screening DAVIO 12-month final data
DAVIO Phase 1 clinical trial showed a 92% reduction in treatment burden at 6 months among subjects with no “excess fluid” at screening (n=9) SOC (Anti-VEGF) + EYP-1901 Low dose (n=2) -89% Low-mid dose (n=1) -100% Mid dose (n=5) -90% High dose (n=1) -100% SOC Anti-VEGF Injections Before and After Treatment Reduction in Average Monthly Treatment Burden at 6 Months Among Eyes Dry at Screening SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit -1 year Month 0 6 months 16 11 10 9 6 5 4 3 1 Time Prior to Treatment with EYP-1901 Time Since EYP-1901 DAVIO 12-month final data
Subgroup Analysis: Supplemental Injection-Free Rates Up to Each Visit in Subjects with No Excess Fluid at Screening (n=9) Median time to supplemental anti-VEGF: 12 months 56% 67% 67% 67% 89% 56% 56% 67% DAVIO Final 12-Months Data 100% 100% 100% 100% DAVIO 12-month final data
EYP-1901 TREAT TO MAINTAIN 20 | INVESTOR PRESENTATION
EYP-1901 demonstrated clinically significant reduction in treatment burden of 75% at 6 Months supporting treat to maintain positioning About half of eyes in DAVIO could go up to 6 months on EYP-1901 alone Another ~30% received only a single supplemental anti-VEGF during 6-months About 15 % failed both SoC and 1901 and required multiple supplements TREAT TO MAINTAIN WITH EYP-1901 21 | INVESTOR PRESENTATION
EYP-1901 positioned as a potential “Treat-to-Maintain” therapy in wet AMD Treat initially with current anti-VEGF standard of care until VA is maximally improved and retina is as dry as possible (induction phase) Maintain with EYP-1901 every six months, supplementing if needed with current anti-VEGF biologic Based on DAVIO, we believe over half of all wet AMD eyes may be maintained visually and anatomically with EYP-1901 alone Another large segment may require occasional supplemental anti-VEGF but a much-reduced interval 22 | INVESTOR PRESENTATION
WET AMD PHASE 2 CLINICAL TRIAL (DAVIO 2) 23 | INVESTOR PRESENTATION EYP-1901
EYP-1901 DAVIO 2 clinical trial is non-pivotal randomized, double-masked, aflibercept controlled -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 EYP-1901 2mg low dose (n=48) EYP-1901 3mg high dose (n=48) Aflibercept q8W (n=48) RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHEDULED EYP-1901 DOSING AFLIBERCEPT q8W EYP-1901/AFLIBERCEPT 1⁰ ENDPOINT BLEND W28 AND W32; UNMASK W32 24 | INVESTOR PRESENTATION
NPDR PHASE 2 CLINICAL TRIAL (PAVIA) 25 | INVESTOR PRESENTATION EYP-1901
Diabetic Retinopathy Market Size Report. 2018-2020 (GrandViewResearch.com), Global Diabetic Retinopathy Market Size Report. Jan. 2022 (MarketDataForecast.com) Rising prevalence of diabetes Growth of the aging population Rising awareness by patients Rising awareness within healthcare Growing Global DR Market $12.27B Analysis includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa $12.27 billion is the estimated market size by 2032, a result of diabetes prevalence and the aging population $6.6B Diabetic Retinopathy Market Multi billion-dollar opportunity Leading cause of blindness Significant need for longer duration treatment
EYP-1901 Phase 2 NPDR PAVIA clinical trial is non-pivotal, randomized double-masked, day-one single injection with sham control EYP-1901 DOSING VISIT SCHEDULED SHAM INJECTION -D21 to –D5 D1 W4 W12 W24 W36 W48 EYP-1901 2mg low dose (n=35) EYP-1901 3mg high dose (n=35) Control Sham (n=35) RANDOMIZATION EYP-1901 1⁰ ENDPOINT UNMASK DATA 27 | INVESTOR PRESENTATION
YUTIQ® –A sustained delivery treatment of posterior segment uveitis using Durasert
Approved for the treatment of posterior segment uveitis Commercially launched in U.S. in 2019 Patent protection to August 2027 Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years LICENSE AGREEMENTS Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA Rights for China, Hong Kong, Taiwan, Macau , Korea and certain SE Asia countries licensed to Ocumension Therapeutics with a royalty on sales payable to EyePoint PRODUCTS CONTINUOUS CALM IN UVEITIS 29 | INVESTOR PRESENTATION
PRODUCTS 60K–100K patients are suffering from posterior segment uveitis in the U.S. The need Flares can cause blindness 30,000 Americans become blind each year because of uveitis Uveitis lasts a lifetime and often affects people in middle age Conventional treatment is burdensome for patients and caregivers The YUTIQ answer 3-year continuous treatment in a single injection that controls flares and preserves eyesight Single injection in the physician’s office Gives patients and physicians the confidence that comes with three years of assured compliance CONTINUOUS CALM IN UVEITIS Posterior segment uveitis can permanently damage vision with every flare 30 | INVESTOR PRESENTATION
PRODUCTS CONTINUOUS CALM IN UVEITIS Continuous 3-year delivery limits blindness-causing flares Time to recurrence of uveitis within 36 months YUTIQ MEDIAN TIME TO FIRST RECURRENCE: 1051 DAYS PROBABILITY RECURRENCE 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 TIME (DAYS) 3 YEARS IMPLANT DEPLETION FAI Insert (N=87) Sham Injection (N=42) US Phase 3 Trial 31 | INVESTOR PRESENTATION
Strong customer demand for YUTIQ continued in Q3 2022 *Customer demand is defined as units purchased by Surgery Centers or physicians from the specialty distributors. PRODUCTS
Balance Sheet – September 30, 2022 $157 million of cash and investments $40 million of short and long-term debt Cash runway into 2H 2024 Solid cash position and cash runway beyond anticipated 2023 value inflection points FINANCIAL SUMMARY Commercial Performance –YTD September 30, 2022 $30 million of net product revenues Commercial franchise projected to break-even in 2022 33 | INVESTOR PRESENTATION
Investor Presentation November 2022